Nebivolol
- Generic Name
- Nebivolol
- Brand Names
- Bystolic
- Drug Type
- Small Molecule
- Chemical Formula
- C22H25F2NO4
- CAS Number
- 118457-14-0
- Unique Ingredient Identifier
- 030Y90569U
- Background
Nebivolol is a racemic mixture of 2 enantiomers where one is a beta adrenergic antagonist and the other acts as a cardiac stimulant without beta adrenergic activity. Treatment with nebivolol leads to a greater decrease in systolic and diastolic blood pressure than atenolol, propranolol, or pindolol. Nebivolol and other beta blockers are generally not first l...
- Indication
Nebivolol is indicated to treat hypertension.
- Associated Conditions
- Hypertension
- Associated Therapies
- -
Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries
- Conditions
- Interventions
- First Posted Date
- 2024-05-22
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 150
- Registration Number
- NCT06424834
- Locations
- 🇺🇸
Stanford Hospital, Palo Alto, California, United States
Beta-blockade in Unruptured Intracranial Aneurysm
- First Posted Date
- 2024-02-08
- Last Posted Date
- 2024-02-08
- Lead Sponsor
- Jagiellonian University
- Target Recruit Count
- 100
- Registration Number
- NCT06249802
- Locations
- 🇵🇱
University Hospital in Krakow, Kraków, Lesser Poland, Poland
Determination of Drug Levels for Pharmacotherapy of Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2023-09-13
- Last Posted Date
- 2024-01-18
- Lead Sponsor
- University Hospital Ostrava
- Target Recruit Count
- 100
- Registration Number
- NCT06035978
- Locations
- 🇨🇿
University Hospital Ostrava, Ostrava, Czech Republic, Czechia
Cardioprotective Effects of Nebivolol Versus Placebo in Patients Undergoing Chemotherapy With Anthracyclines
- Conditions
- Interventions
- First Posted Date
- 2023-02-15
- Last Posted Date
- 2023-02-23
- Lead Sponsor
- Giulio Stefanini
- Target Recruit Count
- 80
- Registration Number
- NCT05728632
- Locations
- 🇮🇹
IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy
Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy
- First Posted Date
- 2022-08-24
- Last Posted Date
- 2023-03-01
- Lead Sponsor
- Menarini International Operations Luxembourg SA
- Target Recruit Count
- 291
- Registration Number
- NCT05513937
- Locations
- 🇧🇬
Medical Center Hera EOOD, Sofia, Bulgaria
Effect of Different Antihypertensive Drugs on Central Blood Pressure
- First Posted Date
- 2022-04-14
- Last Posted Date
- 2022-04-14
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 110
- Registration Number
- NCT05328310
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
24 Hour Ambulatory Cardiac Oxygen Consumption
- Conditions
- Interventions
- First Posted Date
- 2021-12-27
- Last Posted Date
- 2021-12-27
- Lead Sponsor
- State University of New York at Buffalo
- Target Recruit Count
- 26
- Registration Number
- NCT05170061
- Locations
- 🇺🇸
Erie County Medical Center, Buffalo, New York, United States
To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2021-05-17
- Last Posted Date
- 2021-08-04
- Lead Sponsor
- Daewoong Pharmaceutical Co. LTD.
- Target Recruit Count
- 24
- Registration Number
- NCT04888728
- Locations
- 🇰🇷
Inje University Busan Paik Hospital, Busan, Korea, Republic of
Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging
- Conditions
- Interventions
- First Posted Date
- 2019-10-17
- Last Posted Date
- 2023-11-29
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 360
- Registration Number
- NCT04130438
- Locations
- 🇺🇸
Stanford University, Stanford, California, United States
The Effect of Nebivolol in Hypertensive Patients With Coronary Arterial Spasm
- Conditions
- Interventions
- First Posted Date
- 2019-04-29
- Last Posted Date
- 2020-03-10
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 51
- Registration Number
- NCT03930433
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.